Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk node-negative early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

摘要

Background: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast cancer.